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-Transforming growth factor-␤ (TGF-␤) is a key mediator in the pathogenesis of renal diseases. Betaglycan, also known as the type III TGF-␤ receptor, regulates TGF-␤ action by modulating its access to the type I and II receptors. Betaglycan potentiates TGF-␤; however, soluble betaglycan, which is produced by the shedding of the membrane-bound receptor, is a potent antagonist of TGF-␤. In the present work, we have used a recombinant form of soluble betaglycan (SBG) to prevent renal damage in genetically obese and diabetic db/db mice. Eight-wk-old db/db or nondiabetic (db/m) mice were injected intraperitoneally with 50 g of SBG or vehicle alone three times a wk for 8 wk. The db/db mice that received vehicle presented albuminuria and increased serum creatinine, as well as glomerular mesangial matrix expansion. The db/db mice treated with SBG exhibited a reduction in serum creatinine, albuminuria, and structural renal damage. These effects were associated with lower kidney levels of mRNAs encoding TGF-␤1, TGF-␤2, TGF-␤3, collagen IV, collagen I, fibronectin, and serum glucocorticoid kinase as well as a reduction in the immunostaining of collagen IV and fibronectin. Our data indicate that SBG is a renoprotective agent that neutralized TGF-␤ actions in this model of nephropathy. Because SBG has a high affinity for all TGF-␤ isoforms, in particular TGF-␤2, it is found naturally in serum and tissues and its shedding may be regulated. We believe that SBG shall prove convenient for long-term treatment of kidney diseases and other pathologies in which TGF-␤ plays a pathophysiological role. diabetic nephropathy; transforming growth factor-␤; serum glucocorticoid kinase; fibronectin; collagen IV; mesangial matrix expansion TRANSFORMING GROWTH FACTOR-␤ (TGF-␤) is a multifunctional cytokine involved in the control of cellular proliferation and differentiation, development, immune responses, and tissue repair (16, 22) . Deregulated TGF-␤ actions underlie the pathogenesis of oncogenic, autoimmune, and fibrotic diseases (5, 23) . Among the best-characterized examples of how this deregulation results in disease are the nephropathies. An overwhelming amount of evidence indicates that, independently of the etiology, persistent overproduction of TGF-␤ is an important mediator of kidney disease. It has been shown that overexpression of TGF-␤ in an injured glomerulus induces a "profibrotic" feedback loop that overproduces, among others, extracellular matrix components and TGF-␤ itself, resulting in the onset of disease (28, 33) . The fact that many of these events can be blocked by the administration of TGF-␤-neutralizing agents not only confirms the relevant pathophysiological role of TGF-␤ but also supports the anti-TGF-␤ strategies as rational treatments for kidney disease (6, 28) . Relevant for the present work is the demonstration that TGF-␤ also plays a role in the nephropathy exhibited by db/db mice (14, 36) .
TGF-␤ signals through two related transmembrane Ser/ Thr kinase receptors, type I and II receptors, which, on heteromerization by the ligand, phosphorylate members of the Smad family of transcriptional regulators that mediate cellular TGF-␤ responses. In addition to type I and II receptors, there are two TGF-␤ coreceptors, betaglycan and endoglin, that control its access to the kinase receptors (2, 23) . Betaglycan, also known as the type III TGF-␤ receptor, is a membrane proteoglycan with a core protein that binds all TGF-␤ isoforms with high affinity. Betaglycan is a positive regulator of TGF-␤ because it increases the affinity of TGF-␤ binding to the type II receptor, enhancing cell responsiveness to TGF-␤ (21, 25) . Although betaglycan was considered for a long time an "accessory" receptor of TGF-␤, the fact that the betaglycan knockout mouse exhibits an embryonic lethal phenotype indicates otherwise (29) . Adding to the functional complexity of betaglycan is its function as the inhibin coreceptor that mediates its activin antagonism (34) .
Membrane betaglycan also serves as the precursor for a soluble form of the receptor. Soluble betaglycan (SBG) is shed from the membrane-bound receptor by constitutive and regulated proteolytic cleavages of its extracellular region (1, 31) . In contrast to membrane betaglycan, SBG inhibits TGF-␤ binding to kinase receptors and thereby works as a TGF-␤ antagonist (20, 32) . In previous work, we have employed this property of SBG for the reduction of tumor progression and metastasis in xenograft models of breast and prostate cancer as well as for the treatment of murine tuberculosis, diseases mediated, in part, by TGF-␤ (3, 4, 13) . In the present study, we have taken advantage of the potent TGF-␤-neutralizing activity of SBG for treating the db/db mouse, a genetic model of type 2 diabetes that develops a nephropathy that resembles the disease in humans (7, 27) . We found that administration of recombinant SBG decreases both structural and functional renal injury in the db/db mouse. Because of its unique biological features, our findings position SBG as a strong therapeutic anti-TGF-␤ agent.
MATERIALS AND METHODS
Animals and experimental design. Male db/db mice (C57BLKS/J) were purchased from Jackson ImmunoResearch Laboratories (Bar Harbor, ME). The db/db mouse, lacking the hypothalamic leptin receptor, is a model of type 2 diabetes mellitus that exhibits hyperglycemia, hyperinsulinemia, and hyperleptinemia associated with hyperphagia and obesity manifesting at ϳ4 -7 wk after birth (7, 27) . SBG was prepared as a baculoviral recombinant secreted protein and was purified as described before (32) . SBG or vehicle (PBS) was injected intraperitoneally (ip) three times per week over the 8-wk duration of the experiment. Diabetic male db/db mice and their nondiabetic db/m littermates were randomly divided into four groups as follows: db/m PBS (n ϭ 8) or db/db PBS (n ϭ 14), injected with 100 l PBS as control untreated groups, and db/SBG (n ϭ 8) or db/db SBG (n ϭ 14), treated with 50 g SBG as the treated groups. The SBG dose was selected on the basis of unpublished experiments with rats subjected to Anti-Thy-1 nephropathy (Vilchis-Landeros MM, Juárez P, Mendoza V, Bobadilla NA, Aguilar-León D, Hernández-Pando R, and López-Casillas F, unpublished observations), which showed that an effective therapeutic ip dose for rodents was in the range of 0.8 -2 mg/kg. Treatments started at 8 wk of age because 100% of db/db mice become frankly hyperglycemic at this age (27) . All procedures followed were in accordance with our institutional guidelines for animal care. Before death (at 16 wk of age), individual mice were placed in metabolic cages to obtain 24-h urine collections. No sugar was added to the water provided to the mice during the collection period. Urine losses due to evaporation were prevented by overlaying mineral oil in the collection tubes. Serum and urine creatinine were measured with an autoanalyzer (Technicon RA-1000, Bayer, Tarrytown, NY). Creatinine clearance (C cr) was calculated by the standard formula Ccr ϭ UV/P, where U is the concentration of creatinine in urine, V is the urine flow rate, and P is plasma creatinine concentration.
Analysis of SBG tissular distribution. SBG was iodinated by the chloramine T method (8) . Groups of two male db/db or db/m (7-to 9-wk-old) mice were injected with 50 g of cold SBG added to 577,700 counts/min of 125 I-labeled SBG as a tracer in a final volume of 0.1 ml. For death at 0, 0.5, 1, 2, 4, 8, 12, or 24 h, animals were anesthetized by ether inspiration, serum was obtained, and organs were dissected and weighed. Radioactivity in samples was quantified using a Cobra II gamma counter.
Urine albumin assay. Albumin concentrations in 24-h urine samples were measured with a competitive ELISA (10) in which mouse albumin in the soluble phase competes with albumin immobilized onto microtiter wells (250 ng/well) for binding to a horseradish peroxidase-conjugated anti-albumin antibody (Exocell, Philadelphia, PA). To avoid errors from an incomplete urine collection, albumin excretion was also normalized to urine creatinine.
Glomerular histology, morphometry, and immunohistochemistry. After death, kidneys were carefully dissected and weighed. All histological studies were done with nonperfused kidneys. It has been reported that the relative degree of glomerular hypertrophy remains the same, with or without perfusion (27) . One section of renal cortex per mouse was fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned (5 m), and stained with periodic acid-Schiff reagent (PAS). Twenty glomeruli were randomly selected from each animal, and the extent of extracellular mesangial matrix was identified by PAS-positive material and measured using a computer-assisted color image analyzer (QWin-Leica, Milton Keynes, Cambridge, UK). The area of the PAS-positive material in the mesangium was factored by the glomerular tuft area to obtain the fraction of mesangial matrix. For immunohistochemistry, deparaffinized tissue sections were rehydrated and blocked with 3% H 2O2 in methanol followed by antigen retrieval in a microwave oven in 10 mM citrate buffer, pH 6.0, for 5 min. To reduce background components, tissue sections were treated with antibody diluent (Dako, Carpinteria, CA) diluted 1:100 in PBS and then incubated at 4°C overnight with specific primary antibody. Antibodies against collagen IV and fibronectin were purchased from Abcam (Cambridge, UK). Incubation with secondary biotinylated anti-immunoglobulin followed by horseradish peroxidase-conjugated streptavidin (BioGenex, San Ramon, CA) was done according to the manufacturer's instructions. Peroxidase activity was revealed with 3-amino-9-ethyl-carbazole (BioGenex) in acetate buffer containing 0.05% H 2O2. The sections were counterstained with hematoxylin. For the negative nonimmune control slides, the primary antibody was replaced by nonimmune serum.
RT and real-time PCR amplification. Reverse transcription (RT) was carried out using 10 g of total RNA from the kidney of each mouse. RT was performed at 42°C for 50 min in a total volume of 20 l using 200 U of Moloney murine leukemia virus Reverse Transcriptase (Invitrogen), 100 pmol of random hexamers (Invitrogen), 0.5 mmol/l of each dNTP (Sigma, St. Louis MO), and 1ϫ RT buffer (Reaction, Invitrogen). Quantitative real-time PCR amplification was performed using the ABI Sequence Detection System (ABI PRISM 7700). PCR was performed using a Quantitect SYBR Green PCR Kit (Qiagen) in a 25-l reaction volume containing 1 l of cDNA and 20 pm of specific 5Ј-and 3Ј-primers. A dynamic range was built with each product of PCR on copy number serial dilutions of 1 ϫ 10 8 , 1 ϫ ; all PCRs were performed in triplicate. A total of 40 amplification cycles was performed, an initial incubation step of 15 min at 95°C to activate the enzyme, denaturing at 95°C for 30 s, annealing at 60°C for 30 s, and extending at 72°C for 45 s. Standard curves were calculated referring the threshold cycle (the PCR cycle at which a specific fluorescence becomes detectable) to the log of each cDNA dilution step. Results are expressed as the number of copies of target mRNA normalized to 1/100 of the number of copies of acidic ribosomal protein mRNA. All primers were designed using ABI PRISM 7500 system software and were obtained from Sigma-Aldrich Quimica. Nucleotide sequences of primers used are shown in Table 1 .
Statistical analysis. Data are presented as means Ϯ SE, with n representing the number of animals. Groups were analyzed by oneway ANOVA, and the Newman-Keuls test was used to compare difference among the groups. P Ͻ 0.05 was considered significant.
RESULTS

Physiological parameters.
To evaluate whether SBG can prevent TGF-␤-induced kidney damage, we employed genetically obese and diabetic, leptin receptor mutant db/db mice. In the C57BLKS/J genetic background, the db/db mouse exhibits many features of human diabetic nephropathy. Although the db/db mouse does not develop a full-fledged renal insufficiency syndrome (7), it is a good model for human diabetic nephropathy because it presents albuminuria, increased serum creatinine, glomerular mesangial expansion, and kidney histological lesions resembling those found in the human disease (27) . From 8 to 16 wk of age, diabetic db/db mice and their db/m heterozygous nondiabetic littermates were injected intraperitoneally (ip) with 50 g of SBG three times a week. Untreated groups received only vehicle (PBS). The db/db mice remained hyperglycemic and glycosuric throughout the experimental period, and because of glycosuria, urine volumes were markedly increased in both db/db groups ( Table 2) . Body weights at the beginning and at the end of the study were significantly greater in db/db mice than in nondiabetic controls. Kidney weights were significantly greater in db/db compared with db/m mice, and SBG treatment did not modify the kidney weight in either db/db or db/m mice ( Table 2) .
SBG treatment reduced plasma creatinine and albuminuria in db/db mice. At the end of the study, db/db mice treated with PBS developed renal function impairment, as measured by elevated plasma creatinine and urine albumin excretion (Fig.  1) . Similar to what other workers have observed (9, 36) , the plasma creatinine concentration was elevated 2.5-fold in untreated db/db compared with db/m mice. SBG induced a significant reduction in serum creatinine in db/db mice (Fig.  1A) , and creatinine clearance was also improved; however, the difference did not reach statistical significance (Fig. 1B) . To minimize any error due to incomplete urine collection, the absolute urinary albumin excretion (Fig. 1C) and albuminuria calculated as relative ratio to creatinine excretion (Fig. 1D) were evaluated. Albumin excretion was increased more than fourfold in the db/db PBS group compared with the db/m PBS group. SBG treatment of db/db mice resulted in at least a 50% reduction in albuminuria. SBG did not modify albumin excretion in nondiabetic db/m mice.
SBG prevented mesangial expansion in db/db mice. Figure  2A shows representative digitalized photomicrographs of a glomerulus from each experimental group showing diffuse mesangial expansion characterized by an increase in the accumulation of PAS-positive matrix. Figure 2B depicts a morphometric analysis indicating that in db/db mice the mesangial matrix fraction was expanded 2.4-fold compared with db/m mice. This observation is consistent with previous reports by other workers (9, 10, 17, 36) . In db/db mice, SBG administration prevented mesangial expansion to nearly the values seen in db/m mice. Although SBG treatment significantly reduced the mesangial expansion in db/db mice, it did not affect mesangial area in db/m mice. As reported by other workers that have characterized kidney pathology in the db/db mouse (27, 36) , none of our experimental groups presented significant pathological changes in the tubulointerstitial compartment (data not shown).
Body distribution of SBG. To determine SBG body distribution in db/db mice, 50 g of SBG along with a tracer amount of 125 I-labeled SBG were injected ip into 7-to 9-wk-old db/db or db/m mice and its distribution was determined at diverse time intervals by measuring the amount of 125 I in blood and several tissues such as the kidney, liver, lungs, and heart. As shown in Fig. 3A , SBG quickly entered the blood circulation, reaching a peak at 30 min after injection and slowly decreasing to become virtually undetectable at 24 h. Similar half-lives of circulating 125 I-labeled SBG, of ϳ4 h, were observed in both diabetic and nondiabetic mice. Importantly, 125 I-labeled SBG reached the kidneys in diabetic and nondiabetic mice, concentrating ϳ10% of the label after 30 min of injection (Fig. 3, B  and C) .
125 I-labeled SBG was detected in other organs, even at greater amounts than in kidneys as in the case of liver, which accumulated up to 22% of the label at 30 min postinjection. However, considering the absolute organ weight, the kidneys are the organs that better concentrated 125 I-labeled SBG, with values that are two to three times larger than for the liver. After the 30-min maximum, 125 I-labeled SBG disappeared from kidneys, liver, lungs, and heart, following kinetics that mirror its serum levels. Although the graphs shown in Fig. 3 may suggest that 125 I-labeled SBG clears from the serum and kidneys of db/db mice more quickly than from db/m mice, the limited amount of data forbids any statistically significant conclusion. On the other hand, since our SBG treatment schedule consisted of three injections every week and considering 
Primers were designed using Primer Express software in the ABI PRISM 7500 System (Applied Biosystems) using the nucleotide mouse sequences obtained from www.ensemb.org. ID refers to the marker symbol at www.ensemb.org; TGF, transforming growth factor; SGK, serum glucocorticoil kinase; ARP, acidic ribosomal protein, which is the mice ortholog of human acidic ribosomal protein. that the kinetics exhibited by 125 I-labeled SBG, it is safe to conclude that there is at least a 24-h period of a very low level of SBG in the blood and kidney between every injection. Nonetheless, as will be shown by data in the following sections, despite its discontinuous serum levels, SBG effectively decreased the renal expression of genes upregulated by TGF-␤.
TGF-␤ upregulation in kidneys of db/db mice was reversed by SBG. As part of the TGF-␤ pathophysiological mechanism, it has been previously shown that this profibrotic factor upregulates diverse genes in the kidney of diabetic mice. One of the most relevant is TGF-␤1, an effect that has been proposed as responsible for a positive feedback loop that keeps the TGF-␤ signal active during the progression of nephropathies (28, 33) . Therefore, we used real-time RT-PCR to determine the levels of expression of TGF-␤1 and the other two mammalian TGF-␤ isoforms in our experimental groups using the primers indicated in Table 1 . Figure 4 presents a quantitative analysis of TGF-␤1, TGF-␤2, and TGF-␤3 mRNAs showing increases of 2.8-, 2.0-, and 5.0-fold, respectively, in the kidney of control untreated db/db mice compared with their nondiabetic db/m littermates. Importantly, in the diabetic mice treated with SBG it significantly prevented the upregulation of all three TGF-␤ isoform mRNAs, decreasing their levels similar to those in nondiabetic db/m mice. SBG treatment did not show any significant effect on the levels of the TGF-␤ mRNAs in db/m mice.
SBG decreased fibronectin and collagen IV in kidneys of diabetic mice. To test whether the downregulation of the three TGF-␤ isoforms had any effect on extracellular matrix com- ponents, we evaluated by immunohistochemistry glomerular fibronectin and collagen IV. These proteins are well-characterized markers that are increased by TGF-␤ in diverse models of nephropathy (9, 28) . Compared with their nondiabetic littermates, the untreated db/db mice had a threefold increase in glomerular staining for fibronectin and collagen IV (Fig. 5) . Treatment with SBG significantly decreased the levels of these proteins in db/db mice without any effect on db/m mice. Figure 6 depicts the expression of other TGF-␤ gene targets evaluated by real-time RT-PCR using the primers shown in Table 2 . The levels of fibronectin, collagen IV, collagen I, and serum glucocorticoid kinase (SGK) mRNAs in the kidneys of db/m mice were barely detectable by this technique. As expected, the untreated db/db mice exhibited large amounts of these mRNAs. In contrast and in accordance with our immunostaining results, SBG administration to db/db mice resulted in a significant reduction in collagen I, collagen IV, fibronectin, and SGK mRNAs by 3-, 3.3-, 2-and 2-fold, respectively. Similar reductions in the expression of the "ECM markers" collagens and fibronectin by means of TGF-␤ inhibition have been reported before (9, 28) . However, to our knowledge this is the first time that SGK, a "functional marker" of kidney disease (18) , is shown to be downregulated by a TGF-␤ inhibitor. SGK is a serine-threonine kinase that is upregulated by glucose and TGF-␤ and is involved in the regulation of sodium transport; thus it has been proposed as a pathophysiological mediator of diabetic nephropathy (18) . Interestingly, although the treatment with SBG did not completely abolish the expression of SGK, it was capable of decreasing it to 60% despite the continuous hyperglycemia exhibited by these mice (Fig. 6D) .
SBG downregulated TGF-␤-responsive genes in kidneys of diabetic mice.
DISCUSSION
The role of TGF-␤ as the key mediator of kidney disease has been extensively documented and has been reviewed elsewhere (28, 33) . Independently of the etiology, TGF-␤ plays this central pathophysiological role in experimental and human nephropathies. The kidney damage observed in the genetically obese and diabetic db/db mouse is also associated with an increase in renal TGF-␤ signaling (14, 36) . Therefore, we employed the db/db mouse to determine whether SBG, a potent inhibitor of TGF-␤ (32), could block TGF-␤ in vivo and thereby ameliorate the progression of renal injury.
The administration of SBG to db/db mice from 8 to 16 wk of age, a period during which overt nephropathy progresses, resulted in a reduction in kidney damage. Plasma creatinine concentration, albuminuria, and mesangial matrix expansion, which are increased in db/db mice at week 16 (9, 10, 17, 27, 36) , were significantly reduced by the treatment with SBG ( Figs. 1 and 2 ). These findings show that SBG treatment effectively ameliorated key structural and functional aspects of renal injury in db/db mice despite the hyperglycemic state of these animals. One relevant finding of the present study is that despite its short circulating half-life, SBG administration had a lasting effect on the expression of well-known TGF-␤ gene targets. We evaluated SBG tissue distribution after ip administration and found that it becomes readily detectable in serum and diverse organs, especially the kidneys, after 30 min of injection (Fig. 3) . SBG remains in blood circulation with a half-life of ϳ4 h in db/db and db/m mice, becoming barely detectable in blood and tissue after 24 h (Fig. 3) . Importantly, despite not exhibiting constantly high serum concentrations, SBG was able to downregulate TGF-␤-responsive genes that are usually overexpressed in the kidneys of diabetic animals; one such gene is the same TGF-␤. The data in Fig. 4 corroborate the previously known renal overexpression of TGF-␤1 in db/db mice and also document that the other two TGF-␤ isoforms are also upregulated in the kidneys of these animals. As expected, SBG significantly reduced the expression of all TGF-␤ isoforms. This finding is relevant because, despite the fact that TGF-␤1 is the best-studied isoform in regard to renal diseases, there is evidence suggesting similar pathophysiological roles for the other two isoforms. For instance, it has been shown that TGF-␤2 and TGF-␤3 also have fibrogenic effects on cultured kidney cells (35) and in vivo the injection of recombinant human TGF-␤2 to rats and mice induces renal Fig. 7 . Betaglycan (BG) dual modulation of TGF-␤ activities. BG, also known as the type III TGF-␤ receptor, potentiates TGF-␤ actions when it is membrane bound. Shedding of BG extracellular region generates the soluble form of the receptor. Soluble BG still binds TGF-␤ with the high affinity of the membrane BG, but instead of "presenting" it to the type II receptor, soluble BG "sequesters" it and therefore neutralizes its actions (20, 32) . Unique among other TGF-␤ inhibitors is the fact that BG may be subject to regulated shedding of its ectodomain (31), making possible, in principle, control of the relative ratio of the membrane and soluble forms of the receptor, providing a way to switch TGF-␤ actions on or off. fibrosis (15, 19) . In addition to its effect on the expression of the TGF-␤ isoforms, SBG also reduced the kidney levels of collagen IV and fibronectin, as evidenced by a decrease in their immunostaining in SBG-treated db/db kidneys (Fig. 5) . SBG also reduced the overexpression of renal collagen I, collagen IV, fibronectin, and SGK mRNAs in the db/db mouse (Fig. 6) . SGK is upregulated by TGF-␤ in diabetic kidneys, and recent studies have indicated that it may have a prominent role as a "functional mediator" of TGF-␤-dependent kidney damage (18) . To our knowledge, this is the first report of SGK mRNA upregulation in db/db mice, as well as its reduction by a TGF-␤ inhibitor.
Given its powerful in vitro and in vivo anti-TGF-␤ effects (3, 4, 13, 20, 32) , it is very likely that SBG renoprotective actions in the db/db mouse arise from TGF-␤ neutralization. In support of this, other anti-TGF-␤ agents have been tested in the db/db model and shown to restore functional and structural markers of kidney disease. For instance, Ziyadeh et al. (36) used a monoclonal pan-specific anti-TGF-␤ antibody (2G7) that significantly reduced mesangial expansion, plasma creatinine, and creatinine clearance, but failed to reduce albuminuria. In another study, Sugaru et al. (30) demonstrated that SMP-534, an agent that apparently inhibits TGF-␤ via inhibition of p38 MAPK, reduced mesangial expansion, albuminuria, and creatinine clearance, but failed to reduce serum creatinine. Overall, SBG, 2G7, and SMP-534 improved kidney function in db/db mice; however, it is difficult to account for the peculiarities of their therapeutic responses, especially when they are regarded as anti-TGF-␤ agents and therefore should produce equivalent effects. One explanation may reside in their chemical nature and distinct mechanism of action. This is relevant because it is has been proposed that the cross talk between the Smad and other signaling pathways may be important for the onset of TGF-␤-mediated kidney damage (12, 17, 33) . Another explanation may be found in the complexity of the pathophysiology of diabetic kidney damage. Examples are the differential effects of these anti-TGF-␤ agents on albuminuria. As recently reviewed by Shankland (26) , proteinuria is a complex problem whose origin involves several factors (VEGF, nephrin phosphorylation, etc.). The question of which of these factors or pathogenic mechanisms is selectively targeted by SBG therapy is still unanswered and remains the subject of our investigations.
In summary, we have shown that SBG treatment of db/db mice significantly ameliorates the progression of kidney dysfunction, without any apparent negative side effect, as indicated by the lack of gross macroscopic damage of internal organs. This is in agreement with a study that revealed only minimal immunological effects in normal mice after a 12-wklong treatment with an anti-TGF-␤ antibody (24) . Nonetheless, it is clear that a comprehensive study of possible complications derived from long-term systemic inhibition of TGF-␤ is still due. Finally, from all the diverse anti-TGF-␤ agents that have been tested in experimental therapeutics, SBG has some biological properties that could turn advantageous for long-term treatment. For example, since SBG is normally found in serum and extracellular fluids, it is unlikely that its long-term systemic administration would elicit an immune response. Regarding its TGF-␤-neutralizing potency, SBG and anti-TGF-␤ antibodies have similar potencies against the TGF-␤1 isoform; however, because of its higher affinity for TGF-␤2, SBG is 10 times more potent against this isoform (32) . If TGF-␤2 turns out to be as relevant as TGF-␤1 to kidney disease, a pending issue that deserves comprehensive study, then SBG's TGF-␤2 isoform selectivity would be a tremendous asset. However, the property of SBG that makes it stand out from the other inhibitors is the fact that its in vivo generation is amenable to regulation. Ever since the discovery that SBG was, in opposition to its membrane form, an inhibitor of TGF-␤ (20) , it was proposed that this receptor could play a relevant role in the physiological regulation of TGF-␤, working like a "switch" that could turn on its functions as a membrane-bound receptor or turn them off as a soluble one (Fig. 7) . With the discovery that the shedding of membrane betaglycan is a regulated process (31) , and given its widespread expression in almost every cell lineage, it is not difficult to foresee new pharmacological strategies for an anti-TGF-␤ therapy based on betaglycan shedding. Namely, molecules that could promote its shedding would become effective anti-TGF-␤ agents. Further work is in progress in our laboratory to explore the feasibility of these novel strategies.
